Food & Drug Administration v. Alliance for Hippocratic Medicine
Case Overview
A coalition of anti-abortion physicians' groups challenged the FDA's approval of mifepristone and its subsequent actions expanding the drug's availability. The Supreme Court held 9-0 that the plaintiffs lacked Article III standing to challenge the FDA's mifepristone actions because they failed to demonstrate a cognizable injury traceable to the challenged regulatory decisions.
BrynoDC Coverage 1 video
The Facts
The Alliance for Hippocratic Medicine and affiliated physicians challenged the FDA's 2000 approval of mifepristone for medication abortion and later regulatory decisions allowing mail distribution and eliminating in-person dispensing requirements; plaintiffs claimed that as physicians they might be called upon to treat complications from mifepristone use, even though none prescribed the drug or had any regulatory relationship to it.
The Application
The Alliance's claimed injury (potential future treatment of mifepristone-related complications) fails the Article III traceability requirement because it depends on an unbroken chain of independent decisions wholly outside plaintiffs' control: the FDA's approval decision must lead to patient use, which must result in complications, which must then present at plaintiffs' facilities rather than elsewhere. The speculative and attenuated nature of this causal chain, compounded by the fact that plaintiffs had no regulatory obligation tied to mifepristone and no existing patient relationship to anyone likely to use it, rendered the injury insufficiently concrete and imminent to establish standing, particularly where the claimed harm rested entirely on the possibility of treating emergencies that plaintiffs might never encounter.
The Conclusion
**Physicians and organizations that do not prescribe, manufacture, or distribute a regulated drug, and whose claimed injury depends on speculative third-party decisions, lack standing to challenge FDA approval decisions.** Federal courts have no jurisdiction over such suits, leaving questions about the FDA's regulatory authority over mifepristone for future challenges by parties with a direct legal stake.
No circuit court data for this case.
Case Analysis
Facts
The Alliance for Hippocratic Medicine and affiliated physicians challenged the FDA's 2000 approval of mifepristone for medication abortion and later regulatory decisions allowing mail distribution and eliminating in-person dispensing requirements; plaintiffs claimed that as physicians they might be called upon to treat complications from mifepristone use, even though none prescribed the drug or had any regulatory relationship to it.
Issue
Whether physicians who do not prescribe mifepristone and face no regulatory obligation traceable to the challenged FDA decisions have Article III standing based on the speculative possibility of treating complications, with plaintiffs arguing potential emergency treatment obligations constituted injury in fact and the government arguing the claimed injury was too speculative and too attenuated from the FDA's regulatory decisions.
Rule
Article III standing requires a concrete, particularized, actual or imminent injury fairly traceable to the challenged governmental action; a claimed injury that depends on a speculative chain of independent choices by physicians, patients, and other third parties is insufficient to confer standing regardless of the plaintiff's sincere objection to the government action.
Analysis
The Alliance's claimed injury, potential future treatment of mifepristone-related complications, fails the Article III traceability requirement because it depends on an unbroken chain of independent decisions wholly outside plaintiffs' control: the FDA's approval decision must lead to patient use, which must result in complications, which must then present at plaintiffs' facilities rather than elsewhere. The speculative and attenuated nature of this causal chain. Compounded by the fact that plaintiffs had no regulatory obligation tied to mifepristone and no existing patient relationship to anyone likely to use it. Rendered the injury insufficiently concrete and imminent to establish standing, particularly where the claimed harm rested entirely on the possibility of treating emergencies that plaintiffs might never encounter.
Conclusion
**Physicians and organizations that do not prescribe, manufacture, or distribute a regulated drug, and whose claimed injury depends on speculative third-party decisions, lack standing to challenge FDA approval decisions.** Federal courts have no jurisdiction over such suits, leaving questions about the FDA's regulatory authority over mifepristone for future challenges by parties with a direct legal stake.
Notes
OT2023. Added via SCOTUS bulk import 2026-05-14
Overview
The Supreme Court held unanimously that a coalition of anti-abortion physicians and medical organizations lacked Article III standing to challenge the FDA's approval of mifepristone and subsequent regulatory decisions expanding access to the drug. Justice Kavanaugh wrote for a unanimous Court, vacating the Fifth Circuit's judgment and remanding with instructions to dismiss.
Flag an issue
This tracker is maintained by BrynoDC and is free because readers fund it. Support